Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement ⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo ⬇️MMP3 (associated with joint damage), C4M Abs#490 #ACR21 @RheumNow https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x

Skin Findings in Patients of Color with Rheumatic Disease #ACR21. Don't miss lupus panniculitis. https://t.co/kM6XbFtNoW

Brepocitinib (TYK2/JAK1 inhibitor) phase 2b study for PsA treatment ⬆️ACR20, 50, 70 response vs. pbo ⬆️secondary outcomes vs. pbo ⬆️serious AE vs. pbo, ⬆️zoster ⭐️no MACE/VTE/death reported Abs#488 #ACR21 @RheumNow https://t.co/KdAHQGjTMZ https://t.co/ugk3rkxX9t

OK am trying to learn about VEXAS ⬇️hearing, periorbital Edelman, chondritis, VTE, pulmonary infiltrates, Sweets, Arthritis. Genetic adult auto inflammatory syndrome ⬆️Men Rx steroids, then IL6i, etc. IL1i has ⬆️skin reactions 6S410 #ACR21 #gamechanger @RheumNow #ClinicalPearl https://t.co/OYRi1yAal5

Too many great points in this presentation! Making sense of the IL-23 inhibitor failure in axSpA studies. From Dr. Atul Deodhar's presentation at #ACR21 6S403 session @RheumNow https://t.co/Iv0LCNob5J

Abst 0482 Baker and colleagues showed that in patients with Type 2 DM, metformin use is associated with significantly lower risk of developing #OA and time to joint replacement #ACR21 @RheumNow https://t.co/a00g3HMrM0

🚨 DESIRES study. DB RCT in systemic sclerosis. Significant benefit of Rituximab in Rodnan skin score and FVC! Abstr#496 #ACR21 @RheumNow #ACRBest https://t.co/Ta6Cq8XZie

Cool talk by P Grayson - how to design ANCA vasculitis RCTs with biomarkers, umbrella/basket RCT designs to treat pts MORE likely to respond. Also for an individual, following ANCA is not that helpful for altering Rx Take a look at this session GS401 #ACR21 #ACRBest @RheumNow https://t.co/nrapO9i4gw

Abst 0478 Binvignat et al performed hierarchical clustering analysis based on cardinal symptoms in hand OA - Identified 5 Phenotypes - Symptoms correlated with metabolic syndrome, joint destruction & physical and psychological burden #ACR21 @RheumNow https://t.co/O9hweqNIS8

Bimekizumab (IL-17A and IL-17Fi) 3 year safety and efficacy in PsA Phase IIb trial ⭐️no new safety signals ⭐️candida infections were all mild/moderate ⭐️efficacy consistent and maintained Abs#491 #ACR21 @RheumNow https://t.co/BK6xPMqAEM https://t.co/meoPd7k0Xp

Dr. Atul Deodhar with an excellent presentation on treatment in axSpA and axPsA. Note ustekinumab and risankizumab did not show improvement in axSpA. However, these studies did not include axPsA. @ACR21 6S403 @RheumNow https://t.co/F73lvpF2at